May 9 |
Profound Medical Announces First Quarter 2024 Financial Results and Issues Full-Year 2024 Revenue Guidance
|
May 6 |
Growing Body of Clinical Evidence Points to the Potential of Profound Medical’s TULSA Procedure Becoming a Mainstream Treatment Modality Across the Entire Prostate Disease Spectrum
|
May 3 |
In the wake of Profound Medical Corp.'s (TSE:PRN) latest CA$31m market cap drop, institutional owners may be forced to take severe actions
|
Apr 22 |
Profound Medical to Release First Quarter 2024 Financial Results on May 9 – Conference Call to Follow
|
Apr 9 |
Profound Medical to Participate in the 2024 Bloom Burton & Co. Healthcare Investor Conference
|
Apr 6 |
Shareholders in Profound Medical (TSE:PRN) are in the red if they invested three years ago
|